TCON - トラコン・ファ―マシュ―ティカルズ (TRACON Pharmaceuticals Inc.) トラコン・ファ―マシュ―ティカルズ

 TCONのチャート


 TCONの企業情報

symbol TCON
会社名 TRACON Pharmaceuticals Inc (トラコン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 TRACON Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate TRC105 is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102 a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.   トラコン・ファ―マシュ―ティカルズは、米国の臨床バイオ製薬会社。がん、加齢性黄斑変性症(AMD)および線維性疾患の治療のために、製品の開発、実用化に注力する。同社の製品には、血管内皮増殖因子(VEGF)経路の阻害剤と組み合わせ、複数の固形腫瘍タイプの治療のために開発された抗エンドグリン抗体TRC105がある。  TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company's clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.
本社所在地 4350 La Jolla Village Drive Suite 800 San Diego CA 92122 USA
代表者氏名 Charles P. Theuer チャールズP.テュア
代表者役職名 President Chief Executive Officer Principal Financial Officer Principal Accounting Officer Director
電話番号 +1 858-550-0780
設立年月日 38261
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 25人
url www.traconpharma.com
nasdaq_url https://www.nasdaq.com/symbol/tcon
adr_tso
EBITDA EBITDA(百万ドル) -22.85800
終値(lastsale) 1.9
時価総額(marketcap) 56697603.6
時価総額 時価総額(百万ドル) 54.60874
売上高 売上高(百万ドル) 10.49800
企業価値(EV) 企業価値(EV)(百万ドル) 7.49974
当期純利益 当期純利益(百万ドル) -23.50800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 TRACON Pharmaceuticals Inc revenues increased from $1.3M to $3M. Net loss increased 32% to $18.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.84 to -$0.79.

 TCONのテクニカル分析


 TCONのニュース

   TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference  2021/08/03 12:05:00 Intrado Digital Media
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 10, 2021 at 12:00pm Eastern Time.
   TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021  2021/07/28 12:05:00 Intrado Digital Media
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
   TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million  2021/07/22 02:30:00 Intrado Digital Media
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (TRACON or the Company), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,926,702 shares of common stock of the Company at a price to the public of $3.82 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price, less underwriting discounts and commissions. The closing of the public offering is expected to occur on or about July 26, 2021, subject to satisfaction of customary closing conditions.
   TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock  2021/07/21 21:27:00 Intrado Digital Media
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (TRACON or the Company), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 2,617,802 shares of the Companys common stock at a public offering price of $3.82 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 392,670 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 26, 2021, subject to satisfaction of customary closing conditions.
   TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award  2021/07/20 12:05:00 Intrado Digital Media
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi.
   TRACON Pharmaceuticals Announces Orphan Drug Designation  2021/07/03 12:52:48 Intrado Digital Media
TRACON Pharmaceuticals Announces Orphan Drug Designation GlobeNewswire
   Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy?  2021/07/02 13:29:11 Yahoo Finance
Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy? Yahoo Finance
   TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award  2021/06/30 12:05:00 Intrado Digital Media
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Ya Huang as Executive Director of Statistical Programming and the grant of an inducement equity award to Mr. Huang.
   Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA  2021/06/30 00:55:00 PR Newswire Asia (English)
SUZHOU, China , June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to envafolimab (KN035), a recombinant humanized PD-L1 single-domain antibody independently invented by Alphamab Oncology, for the treatment of patients with soft tissue sarcoma. This is the second Orphan Drug Designation for Envafolimab after its first ODD in advanced biliary tract cancer and fourth ODD that Alphamab Oncology has obtained from the U.S. FDA. The Orphan Drug Act was passed in 1983 and Orphan Drug Designation is granted by the U.S. FDA to drugs or biologics intended to treat a rare disease or condition, defined as one that affects fewer than 200,000 people in the United States . Programs with Orphan Drug status receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity. Obtaining the Orphan Drug Designation is of great significance for accelerating the development and marketing of new drugs.
   TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma  2021/06/29 12:05:00 Intrado Digital Media
Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials
   TRACON posts promising data from early-stage uliledlimab combo cancer trial  2021/06/04 13:11:23 Seeking Alpha
   TRACON gets positive Independent Data Monitoring Committee recommendation for envafolimab trial  2021/06/01 13:05:11 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 トラコン・ファ―マシュ―ティカルズ TCON TRACON Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)